Primary Endpoints in Pediatric Efficacy Trials Submitted to the US FDA

Documenti analoghi

• Surrogate Endpoints in Pediatric Studies Submitted to the US FDA
  di: Green, Dionna J., et al.
  Pubblicazione: (2018)
• Combined Pediatric and Adult Trials Submitted to the US Food and Drug Administration 2012–2018
  di: Tanaudommongkon, Irin, et al.
  Pubblicazione: (2020)
• Enrichment Strategies in Pediatric Drug Development: An Analysis of Trials Submitted to the US Food and Drug Administration
  di: Green, Dionna J., et al.
  Pubblicazione: (2018)
• A Comparison of Pediatric and Adult Safety Studies for Antipsychotic and Antidepressant Drugs Submitted to the United States Food and Drug Administration
  di: Liu, Xiaomei I., et al.
  Pubblicazione: (2019)
• Monoclonal Antibodies and Fc‐Fusion Proteins for Pediatric Use: Dosing, Immunogenicity, and Modeling and Simulation in Data Submitted to the US Food and Drug Administration
  di: Liu, Xiaomei I., et al.
  Pubblicazione: (2019)